Glycogen Storage Disease - 49 Studies Found

Completed : Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT
: Glycogen Storage Disease Type II
: 2016-04-26
: Other: observation study observation study
Withdrawn : High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease
: Glycogen Storage Disease Type II
: 2012-08-01
: Other: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
Completed : Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies
:
  • Pompe Disease Infantile-Onset
  • Glycogen Storage Disease Type II<
    : 2008-09-30
    : Biological: Myozyme 10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
Completed : Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
:
  • Glycogen Storage Disease Type II
  • Glycogen
    : 2003-12-23
    : Biological: Myozyme 20 mg/kg Other Name: Alglucosida
Approved for marketing : Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
:
  • Glycogen Storage Disease Type II
  • Glycogen
    : 2003-12-23
    : Biological: alglucosidase alfa 20 mg/kg qow Other Na
Active, not recruiting : Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial
:
  • Glycogen Storage Disorder Type 1
  • Hypoglycemia
  • Pompe Disease Late-Onset
  • Glycogen Storage Disease Type II GSD I
    : 2008-10-02
    : Biological: Myozyme 30 mg/kg qow f and 40 mg/kg qow
Completed : Newborn Screening Assay of Pompe's Disease
: Pompe Disease
: 2008-07-09
: Other: Pompe disease newborn screening DBS will be tested for acid alpha-glucosidase (GAA)activity. Newb
Terminated : Study to Evaluate the Safety of AT2220 in Pompe Disease
: Pompe Disease
: 2008-05-30
:
  • Drug: AT2220

Completed : Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
: Pompe Disease
: 2013-09-11
:
  • Drug: Clenbuterol
  • Drug: Placebo
<<< Previous | Next >>>